At a glance
ClinicalIndex Comparison RecordN/ACompleted· 111 enrolled
Drug / intervention
Bevacizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Observational and Prospective Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Patients With Metastatic HER 2-Negative and Aggressive Disease Criteria
In Brief
An observational study evaluating Bevacizumab and Paclitaxel for Breast Cancer. Completed, enrolled 111 participants across 25 sites.
Detailed Summary
This multicenter, observational, prospective study will identify a powerful and easy predictive/prognostic marker to use with participants under bevacizumab.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesSpain
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartDec 2015
Primary CompletionDec 2018
TodayJul 2026
First PostedNov 24, 2015
Enrollment StartDec 9, 2015
Primary CompletionDec 3, 2018
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 10.6 years ago
Interventions
Bevacizumabdrug
Bevacizumab will be administered as per local clinical practice and local labeling.
Paclitaxeldrug
Paclitaxel will be administered as per local clinical practice and local labeling.